Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Nira Hadar"'
Autor:
Umberto Vitolo, Grzegorz S. Nowakowski, John M. Burke, Christopher P. Fox, Marek Trneny, Annalisa Chiappella, Maeve Waldron-Lynch, Nira Hadar, Alok Pachori, Georg Lenz
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S352-S353
Autor:
Joseph Tringali, Christina Amidei, Patrick Y. Wen, John Loewy, Wenya Linda Bi, Kyla A. Truman, Nathan Demars, Leah Seften, Rimas V. Lukas, Jill Buck, E. Antonio Chiocca, Nira Hadar, Dan Triggs, Arnold Gelb, Kamal Chadha, Ganesh Rao, Grace E. Park, James Grant, Pierpaolo Peruzzi, Taylor Estupinan, David A. Reardon, Clark C. Chen, Laurence J.N. Cooper, John Miao
Publikováno v:
Neuro Oncol
Background Veledimex (VDX)-regulatable interleukin-12 (IL-12) gene therapy in recurrent glioblastoma (rGBM) was reported to show tumor infiltration of CD8+ T cells, encouraging survival, but also up-regulation of immune checkpoint signaling, providin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03f3b57f3cf7f1182cf02ed4925d31a2
https://europepmc.org/articles/PMC9159462/
https://europepmc.org/articles/PMC9159462/
Autor:
Umberto Vitolo, Grzegorz S. Nowakowski, John M. Burke, Christopher P. Fox, Marek Trneny, Annalisa Chiappella, Maeve Waldron-Lynch, Nira Hadar, Alok Pachori, Georg Lenz
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S163
Autor:
David Belada, Katerina Kopeckova, Juan Miguel Bergua Burgues, Don Stevens, Grzegorz S. Nowakowski, Maeve Waldron-Lynch, Nira Hadar, Johannes Weirather, Charlotte Lässig, Derek Blair, Martin Dreyling
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S352
Autor:
Umberto Vitolo, Grzegorz S. Nowakowski, John M. Burke, Christopher P. Fox, Marek Trneny, Annalisa Chiappella, Maeve Waldron-Lynch, Nira Hadar, Alok Pachori, Georg Lenz
Publikováno v:
Journal of Clinical Oncology. 40:TPS7590-TPS7590
TPS7590 Background: Up to 40% of patients relapse or are refractory (R/R) to R-CHOP, the current standard of care for diffuse large B-cell lymphoma (DLBCL), indicating an unmet need, particularly in patients with high-intermediate and high-risk disea
Autor:
Jill Buck, Yunxia Wang, Nira Hadar, Laurence J.N. Cooper, Nathan Demars, John Miao, John Loewy, John S. Yu, Nancy Ann Oberheim Bush, Rimas V. Lukas, Joseph Landolfi, Arnold Gelb, Robert Cavaliere, Sylvia Kurz, E. Antonio Chiocca
Publikováno v:
Neuro Oncol
Ad-RTS-hIL-12 (Ad) is a gene therapy candidate for intratumoral (IT) delivery that conditionally expresses IL-12 (IL-12) under the transcriptional control of orally administered veledimex (V) acting via the RheoSwitch Therapeutic Systemâ gene switch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28c81a9468f41bd3331cc06fa6cc0f2f
https://europepmc.org/articles/PMC7650356/
https://europepmc.org/articles/PMC7650356/
Autor:
Nate Demars, John S. Yu, Kamal Chadha, John Loewy, Nancy Ann Oberheim-Bush, Rimas V. Lukas, Christina Amidei, Jill Buck, Nira Hadar, Taylor Estupinan, Laurence J.N. Cooper, Robert Cavaliere, E. Antonio Chiocca, Christine Cordova, Clark C. Chen, Joseph Landolfi, John Miao
Publikováno v:
Neuro Oncol
Ad-RTS-hIL-12(Ad) is a gene therapy candidate conditionally expressing IL-12 under the transcriptional control of veledimex(V) acting via the RheoSwitch Therapeutic System® gene switch. Veledimex plasma and tumor PK demonstrated a dose-response rela
Autor:
Laurence J.N. Cooper, Erin Walsh, John Miao, Arnold Gelb, Sabine Mueller, Rudy Allen, Amanda Saratsis, Nira Hadar, Stewart Goldman, Taylor Estupinan, Jill Buck, Nathan Demars, Susan N. Chi
Publikováno v:
Neuro Oncol
DIPG, which is the leading cause of pediatric brain cancer death with no effective treatment, has neither a highly immunosuppressive nor inflammatory tumor microenvironment (TME). Therefore, eliciting a pro-inflammatory TME may provide therapeutic be
Autor:
Yunxia Wang, Taylor Estupinan, Rimas V. Lukas, Christina Amidei, John Loewy, Nathan Demars, Jill Buck, Arnold Gelb, Ganesh Rao, Nira Hadar, E. Antonio Chiocca, Laurence J.N. Cooper, John Miao, Clark C. Chen
Publikováno v:
Neuro Oncol
A published clinical trial of veledimex (V)-regulatable interleukin-12 (IL-12) gene therapy (“Controlled IL-12”) under the control of a transcriptional switch (RheoSwitch Therapeutic Systemâ, RTSâ) as monotherapy in recurrent glioblastoma (rGBM
Autor:
John Loewy, Christina Amidei, Jill Buck, E. Antonio Chiocca, John S. Yu, Yunxia Wang, Nira Hadar, Arnold Gelb, Nathan Demars, Bakhtiar Yamini, Nancy Ann Oberheim Bush, Rimas V. Lukas, Taylor Estupinan, Laurence J.N. Cooper, John Miao
Publikováno v:
Journal of Clinical Oncology. 38:3040-3040
3040 Background: Interleukin-12 (IL-12), a master regulator of the immune system, results in anti-tumor responses in preclinical models, but safe use requires tightly controlled production. This phase 1 trial (NCT02026271) is the first to evaluate th